NEW YORK, Dec. 14 – Orchid BioSciences said Friday it had granted Quest Diagnostics a non-exclusive license to use its SNP-IT technology in its diagnostic tests.

This deal marks the first time Orchid’s technology has been licensed for use in diagnostics.

Under the terms of the deal, Orchid of Princeton, NJ, received an upfront payment of an undisclosed amount and will also be entitled to royalties for diagnostic services Quest provides using Orchid’s technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.